Tepoxalin, sold under the brand name Zubrin[1] among others, is a non-steroidal anti-flammatory drug (NSAIDs) generally used in veterinary medicine to reduce swelling in animals with osteoarthritis.

[1] In rare circumstances, tepoxalin can also be used in human pharmacology to relieve pain caused by musculoskeletal conditions such as arthritis and hip dysplasia.

[1] The Committee for Medicinal Products for Veterinary Use (CVMP) approved tepoxalin as a drug for animals to reduce inflammation and control pain.

[4] In September 2017, an application was submitted to the European Medicines Agency (EMEA) asking for an extension of marketing authorisation for tepoxalin.

[8] When tepoxalin is administered in cats, a drunken-like state afflicting the central nervous system has been recorded on rare occasions.

[8] When administered to horses, the formulation can be a paste, powder or feed-in form which can be fed orally or it can be injected intravenously but no other place in the equine body, as it can cause tissue damage.

Phenylbutazone was formerly used as treatment, but when administered to horses at high doses, it can cause ulcers of the glandular stomach, oral cavity and colon.

[10] Due to the major adverse effects of phenylbutazone, the replacement by tepoxalin was made to reduce muscular pain in 2003.

[11] Common side effects of the consumption of tepoxalin include vomiting, diarrhoea, blood in faeces, loss of appetite, fatigue, thirst, an increase in urination and behavioural changes.

[10] In animals with a history of internal bleeding or low blood pressure, it can result in perforation of the stomach walls or intestinal mucosa.

Signs of overdose or toxicity in canines and felines include tremors, seizures, abnormal behaviour, vomiting and weakness.